A comparison of FLAG-Ida and daunorubicin combined with clofarabine in high-risk acute myeloid leukaemia: data from the UK NCRI AML17 Trial

被引：18
|
作者：
Burnett, A. K. [1 ]
Hills, R. K. [2 ]
Nielsen, O. J. [3 ]
Freeman, S. [4 ]
Ali, A. [5 ]
Cahalin, P. [6 ]
Hunter, A. [7 ]
Thomas, I. F. [2 ]
Russell, N. H. [8 ]
机构：
[1] Cardiff Univ, Sch Med, Cardiff, S Glam, Wales
[2] Cardiff Univ, Ctr Trials Res, Cardiff, S Glam, Wales
[3] Rigshosp, Dept Haematol, Copenhagen, Denmark
[4] Univ Birmingham, Inst Immunol & Immunotherapy, Birmingham, W Midlands, England
[5] Castle Hill Hosp, Dept Haematol, Kingston Upon Hull, N Humberside, England
[6] Blackpool Victoria Hosp, Dept Haematol, Blackpool, England
[7] Leicester Royal Infirm, Dept Haematol, Leicester, Leics, England
[8] Nottingham Univ Hosp NHS Trust, Dept Haematol, Nottingham, England
来源：
LEUKEMIA | 2018年 / 32卷 / 12期
关键词：
CHEMOTHERAPY; YOUNGER; ADULTS;
D O I：
10.1038/s41375-018-0148-3
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
[No abstract available]
引用
收藏
页码：2693 / 2697
页数：5
相关论文
共 7 条
  • [1] A randomised comparison of FLAG-Ida versus daunorubicin combined with clofarabine in relapsed or refractory acute myeloid leukaemia: Results from the UK NCRI AML17 trial
    Russell, Nigel H.
    Hills, Robert K.
    Kjeldsen, Lars
    Clark, Richard E.
    Ali, Sahra
    Cahalin, Paul
    Thomas, Ian F.
    Burnett, Alan K.
    BRITISH JOURNAL OF HAEMATOLOGY, 2022, 198 (03) : 528 - 534
  • [2] A randomized comparison of CPX-351 and FLAG-Ida in adverse karyotype AML and high-risk MDS: the UK NCRI AML19 trial
    Othman, Jad
    Wilhelm-Benartzi, Charlotte
    Dillon, Richard
    Knapper, Steve
    Freeman, Sylvie D.
    Batten, Leona M.
    Canham, Joanna
    Hinson, Emily L.
    Wych, Julie
    Betteridge, Sophie
    Villiers, William
    Kleeman, Michelle
    Gilkes, Amanda
    Potter, Nicola
    Overgaard, Ulrik Malthe
    Mehta, Priyanka
    Kottaridis, Panagiotis
    Cavenagh, Jamie
    Hemmaway, Claire
    Arnold, Claire
    Dennis, Mike
    Russell, Nigel H.
    BLOOD ADVANCES, 2023, 7 (16) : 4539 - 4549
  • [3] Comparison of HiDAC Versus FLAG-IDA in the Treatment of Relapsed Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome
    Tang, Man Wai
    van der Tuin, Deborah
    Aydin, Mesire
    Heijmans, Jarom
    van de Loosdrecht, Arjan A.
    Meijer, Ellen
    Rutten, Caroline E.
    Wondergem, Marielle
    Janssen, Jeroen J. W. M.
    Donker, Marjolein L.
    Hazenberg, Mette D.
    Zweegman, Sonja
    Biemond, Bart J.
    De Leeuw, David C.
    Nur, Erfan
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2025, 114 (04) : 620 - 625
  • [4] Addition of the mammalian target of rapamycin inhibitor, everolimus, to consolidation therapy in acute myeloid leukemia: experience from the UK NCRI AML17 trial
    Burnett, Alan K.
    Das Gupta, Emma
    Knapper, Steve
    Khwaja, Asim
    Sweeney, Marion
    Kjeldsen, Lars
    Hawkins, Timothy
    Betteridge, Sophie E.
    Cahalin, Paul
    Clark, Richard E.
    Hills, Robert K.
    Russel, Nigel H.
    HAEMATOLOGICA, 2018, 103 (10) : 1654 - 1661
  • [5] A randomized comparison of daunorubicin 90 mg/m2 vs 60 mg/m2 in AML induction: results from the UK NCRI AML17 trial in 1206 patients
    Burnett, Alan K.
    Russell, Nigel H.
    Hills, Robert K.
    Kell, Jonathan
    Cavenagh, Jamie
    Kjeldsen, Lars
    McMullin, Mary-Frances
    Cahalin, Paul
    Dennis, Mike
    Friis, Lone
    Thomas, Ian F.
    Milligan, Don
    Clark, Richard E.
    BLOOD, 2015, 125 (25) : 3878 - 3885
  • [6] Treatment intensification with FLAG-Ida may improve disease control in younger patients with secondary acute myeloid leukaemia: long-term follow up of the MRC AML15 trial
    Russell, Nigel
    Hills, Robert
    Kjeldsen, Lars
    Dennis, Mike
    Burnett, Alan
    BRITISH JOURNAL OF HAEMATOLOGY, 2022, 196 (06) : 1344 - 1347
  • [7] Phase I/II study on cytarabine and idarubicin combined with escalating doses of clofarabine in newly diagnosed patients with acute myeloid leukaemia and high risk for induction failure (AMLSG 17-10 CIARA trial)
    Krauter, Juergen
    Fiedler, Walter
    Schlenk, Richard F.
    Paschka, Peter
    Thol, Felicitas
    Luebbert, Michael
    Wattad, Mohammed
    Verbeek, Mareike
    Koenecke, Christian
    Neuhaus, Barbara
    Papkalla, Armin
    Kebenko, Maxim
    Janning, Melanie
    Doehner, Konstanze
    Gaidzik, Verena I.
    Becker, Heiko
    Greil, Christine
    Reimer, Peter
    Goetze, Katharina S.
    Doehner, Hartmut
    Ganser, Arnold
    Heuser, Michael
    BRITISH JOURNAL OF HAEMATOLOGY, 2018, 183 (02) : 235 - 241
1